TempraMed Technologies Valuation Multiples

Discover revenue and EBITDA valuation multiples for TempraMed Technologies and similar public comparables like Carelabs, ContextVision, Doctor Care Anywhere, Jin Medical International and more.

TempraMed Technologies Overview

About TempraMed Technologies

TempraMed Technologies Ltd develops patent-protected solutions for managing and protecting temperature-sensitive medications. Its product range includes VIVI Cap for insulin pens and VIVI Epi for epinephrine injectors, which are distributed through pharmacy and retail networks globally. TempraMed generates the majority of its revenue from the sales of these devices, serving patients, healthcare providers, and pharmacy systems through operations in Southeast Asia, Europe, and Central America. The company enhances its reach by forming partnerships in the healthcare sector to broaden its access and drive usage in various geographic markets.


Founded

2023

HQ

Canada

Employees

10

Financials (FY)

Revenue: $2M
EBITDA: ($18M)

EV

$28M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

TempraMed Technologies Financials

TempraMed Technologies reported last fiscal year revenue of $2M and negative EBITDA of ($18M).

In the same fiscal year, TempraMed Technologies generated $896K in gross profit, ($18M) in EBITDA losses, and had net loss of ($18M).


TempraMed Technologies P&L

In the most recent fiscal year, TempraMed Technologies reported revenue of $2M and EBITDA of ($18M).

TempraMed Technologies is unprofitable as of last fiscal year, with gross margin of 49%, EBITDA margin of (957%), and net margin of (987%).

See analyst estimates for TempraMed Technologies
Last FY202320242025202620272028
Revenue$2M-$2M$2M
Gross Profit$896K-$1M$896K
Gross Margin49%-63%49%
EBITDA($18M)($3K)($18M)($18M)
EBITDA Margin(957%)-(793%)(957%)
EBIT Margin(244%)-(106%)(244%)
Net Profit($18M)($3K)($19M)($18M)
Net Margin(987%)-(845%)(987%)
Net Debt$308K---

Financial data powered by Morningstar, Inc.

TempraMed Technologies Stock Performance

TempraMed Technologies has current market cap of $27M, and enterprise value of $28M.


TempraMed Technologies' stock price is $0.34.

TempraMed Technologies has an EPS (earnings per share) of $-0.23.

See more trading valuation data for TempraMed Technologies
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$28M$27M-0.2%---$-0.23

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

TempraMed Technologies Valuation Multiples

TempraMed Technologies trades at 15.2x EV/Revenue multiple, and (1.6x) EV/EBITDA.

See NTM and 2027E valuation multiples for TempraMed Technologies

TempraMed Technologies Financial Valuation Multiples

As of August 14, 2026, TempraMed Technologies has market cap of $27M and EV of $28M.

TempraMed Technologies has a P/E ratio of (1.5x).

Last FY202320242025202620272028
EV/Revenue15.2x-12.3x15.2x
EV/EBITDA(1.6x)n/m(1.6x)(1.6x)
EV/EBIT(6.2x)n/m(11.7x)(6.2x)
EV/Gross Profit31.2x-19.7x31.2x
P/E(1.5x)n/m(1.4x)(1.5x)
EV/FCF(7.3x)-n/m(7.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified TempraMed Technologies Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

TempraMed Technologies Margins & Growth Rates

In the most recent fiscal year, TempraMed Technologies reported gross margin of 49%, EBITDA margin of (957%), and net margin of (987%).

See estimated margins and future growth rates for TempraMed Technologies

TempraMed Technologies Margins

Last FY20242025202720282029
Gross Margin49%63%49%
EBITDA Margin(957%)(793%)(957%)
EBIT Margin(244%)(106%)(244%)
Net Margin(987%)(845%)(987%)
FCF Margin(207%)(3%)(207%)

TempraMed Technologies Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth-(19%)
Gross Profit Growth-(37%)
EBITDA Growth596907%(2%)
EBIT Growth79370%87%
Net Profit Growth635914%(5%)
FCF Growth-5546%

Data powered by FactSet, Inc. and Morningstar, Inc.

TempraMed Technologies Operational KPIs

TempraMed Technologies' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.

Access forward-looking KPIs for TempraMed Technologies
Last FY20242025202620272028
Revenue per Employee$0.2M--
Opex per Employee$0.5M--
S&M Expenses to Revenue120%88%120%
G&A Expenses to Revenue147%74%147%
R&D Expenses to Revenue16%6%16%
Opex to Revenue292%168%292%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

TempraMed Technologies Competitors

TempraMed Technologies competitors include Carelabs, ContextVision, Doctor Care Anywhere, Jin Medical International, Cambridge Cognition, Rockwell Medical, NextPlat, Healixa, CareView Communications and Prolight Diagnostics.

Most TempraMed Technologies public comparables operate across Medical Supplies, Healthcare Software, B2B SaaS, Vertical SaaS and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Carelabs0.0x-0.1x-
ContextVision1.9x1.7x28.4x9.2x
Doctor Care Anywhere0.6x0.6x5.4x4.8x
Jin Medical International0.8x-17.0x-
Cambridge Cognition1.9x1.6x(26.5x)(54.4x)
Rockwell Medical0.3x0.3x(10.0x)16.6x
NextPlat0.2x0.3x(1.4x)-
Healixa----

This data is available for Pro users. Sign up to see all TempraMed Technologies competitors and their valuation data.

Start Free Trial

TempraMed Technologies VC Funding History

Before going public, TempraMed Technologies raised $5M in total equity funding, across 1 round.


TempraMed Technologies Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Sep-25Series A-$5M-TempraMed Technologies Ltd. is a medical technology company developing solutions for storing and managing temperature-sensitive medications, including products like VIVI Cap and VIVI Epi. The company operates in North America, Europe, and Asia, with distribution partnerships and plans for new product launches. In September 2025, TempraMed closed an oversubscribed C$7.4 million private placement financing ahead of its public listing on the Canadian Securities Exchange under ticker VIVI via reverse takeover, with trading anticipated mid-September 2025. It also listed on the Frankfurt Stock Exchange under 9DY and raised additional funds in November 2025. Earlier, in early 2025, TempraMed closed a C$2.5 million fully subscribed private placement issuing units at $0.76 each for working capital and inventory buildup. The company projects production capacity of 1M units/year, equivalent to ~US$70 million in sales, and anticipates +US$5.0M in 2025 with cash flow positivity targeted for later periods.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About TempraMed Technologies

When was TempraMed Technologies founded?TempraMed Technologies was founded in 2023.
Where is TempraMed Technologies headquartered?TempraMed Technologies is headquartered in Canada.
How many employees does TempraMed Technologies have?As of today, TempraMed Technologies has over 10 employees.
Is TempraMed Technologies publicly listed?Yes, TempraMed Technologies is a public company listed on Canadian Securities Exchange.
What is the stock symbol of TempraMed Technologies?TempraMed Technologies trades under VIVI ticker.
When did TempraMed Technologies go public?TempraMed Technologies went public in 2025.
Who are competitors of TempraMed Technologies?TempraMed Technologies main competitors include Carelabs, ContextVision, Doctor Care Anywhere, Jin Medical International, Cambridge Cognition, Rockwell Medical, NextPlat, Healixa, CareView Communications, Prolight Diagnostics.
What is the current market cap of TempraMed Technologies?TempraMed Technologies' current market cap is $27M.
What is the current revenue of TempraMed Technologies?TempraMed Technologies' last fiscal year revenue is $2M.
What is the current EV/Revenue multiple of TempraMed Technologies?Current revenue multiple of TempraMed Technologies is 15.2x.
Is TempraMed Technologies profitable?No, TempraMed Technologies is not profitable.
How many companies TempraMed Technologies has acquired to date?TempraMed Technologies hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies TempraMed Technologies has invested to date?TempraMed Technologies hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to TempraMed Technologies

Lists including TempraMed Technologies

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial